Fitbit has invested $6 million in a glucose-monitoring startup called Sano, in what appears to be part of Fitbit’s larger plans to make its fitness devices more valuable for overall health.
The investment was first reported by CNBC earlier today; The Verge independently confirmed the investment.
Sano, founded in 2011, is a San Francisco-based company that has been working on what it describes as a minimally invasive, continuous glucose monitor that you’d wear on your skin like a patch. The product doesn’t appear to have shipped yet, and it’s unclear whether this would be sold directly to consumers, or whether it will require FDA approval. That depends on what kind of claims the company is making about the technology.